AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
Details of the oral presentations are as follows:
Presentation Title: Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Pediatric and Adult Patients Following Allogeneic Hematopoietic Stem Cell Transplantation
Presenter:
Assigned session: Oral Abstract - Session C - Health Services
Session Date & Time:
Presentation Tine: 2:30 –
Abstract Number: 19
Presentation Title: Economic Burden and Health Resource Utilization Associated with dsDNA Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
Presenter:
Assigned session: Oral Abstract - Session C - Health Services
Session Date & Time:
Presentation Time: 3:15 –
Abstract Number: 22
Presentation Title: Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Lymphocytes for the Treatment of Virus-Associated Hemorrhagic Cystitis in the Post-HSCT Setting
Presenter:
Assigned session: Oral Abstract -
Session Date & Time:
Presentation Time: 4:45 –
Abstract Number: 95
Details of the poster presentations are as follows:
Presentation Title: Allogeneic, Off-the-Shelf, Sars-CoV-2-Specific T Cells to Treat High-Risk Patients with COVID-19
Presenter:
Poster number: 422
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding AlloVir’s development and regulatory status of our product candidates and its strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to AlloVir’s financial results, the timing for completion of AlloVir’s clinical trials of its product candidates, whether and when, if at all, AlloVir’s product candidates will receive approval from the
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005938/en/
Media contact:
ScientPR
AlloVirPR@scientpr.com
617-872-2462
Investor contact:
ir@allovir.com
Source: